Dose and schedule finding of post-BMT Decitabine Treatment For up to 2 years after the start of Decitabine [clinicaltrials_resource:ec3f5b29ee394bd2a2609bcc00ddd837]
To find the safe dose and schedule of administration of the drug decitabine that can be given to patients with higher risk MDS or secondary AML evolving from MDS who received allogeneic stem cell transplantation
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Dose and schedule finding of post-BMT Decitabine Treatment For up to 2 years after the start of Decitabine [clinicaltrials_resource:ec3f5b29ee394bd2a2609bcc00ddd837]
To find the safe dose and schedule of administration of the drug decitabine that can be given to patients with higher risk MDS or secondary AML evolving from MDS who received allogeneic stem cell transplantation
Bio2RDF identifier
ec3f5b29ee394bd2a2609bcc00ddd837
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:ec3f5b29ee394bd2a2609bcc00ddd837
measure [clinicaltrials_vocabulary:measure]
Dose and schedule finding of post-BMT Decitabine Treatment
time frame [clinicaltrials_vocabulary:time-frame]
For up to 2 years after the start of Decitabine
description
To find the safe dose and sche ...... neic stem cell transplantation
identifier
clinicaltrials_resource:ec3f5b29ee394bd2a2609bcc00ddd837
title
Dose and schedule finding of p ...... after the start of Decitabine
@en
type
label
Dose and schedule finding of p ...... f5b29ee394bd2a2609bcc00ddd837]
@en